Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acetylsalicylic acid · 1 trial · 1 indication
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (\>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of \>=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - \<5 g/dl (or drop in hematocrit of 9 - \<15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event.
| Arm | Type | Description |
|---|---|---|
| Stratum 1/ASA | ACTIVE_COMPARATOR | Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier. |
| Stratum 1/Rivaroxaban | EXPERIMENTAL | Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier. |
| Stratum 2/ASA | ACTIVE_COMPARATOR | ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier. |
| Stratum 2/Rivaroxaban | EXPERIMENTAL | Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier. |
| Name | Type | Description |
|---|---|---|
| Acetylsalicylic acid | DRUG | ASA 100 mg enteric-coated tablet once daily orally. |
| Rivaroxaban | DRUG | Rivaroxaban 2.5 mg tablet twice daily orally. |
| Clopidogrel | DRUG | Clopidogrel 75 mg once daily orally. |
| Ticagrelor | DRUG | Ticagrelor 90 mg twice daily orally. |
Inclusion Criteria: * Participants, 18 years or older, must have symptoms suggestive of acute coronary syndrome (ACS) (angina, or symptoms thought to be equivalent) within 48 hours of hospital presentation, or developed ACS while being hospitalized, and has a diagnosis of: a) ST segment elevation m...
Acetylsalicylic acid is a small molecule being studied for use in Acute Coronary Syndrome, a cardiovascular condition. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being evaluated in a clinical trial setting, and its safety and efficacy are being assessed in patients with this condition.
Acetylsalicylic acid is a small molecule being developed for Acute Coronary Syndrome. The specific molecular target of this drug has not been disclosed in the available information. It is being studied in a Phase 2 clinical trial to evaluate its safety and efficacy in patients with Acute Coronary Syndrome.
Acetylsalicylic acid is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker JNJ. The drug is currently in Phase 2 clinical development for the treatment of Acute Coronary Syndrome, a cardiovascular condition.
Acetylsalicylic acid is in Phase 2 clinical development. It is an investigational drug being studied for Acute Coronary Syndrome. The drug has completed one Phase 2 clinical trial, and it is not yet approved by regulatory authorities. Further clinical development may be needed before it can be considered for approval.
Acetylsalicylic acid has been studied in one clinical trial with the identifier NCT02293395. This Phase 2 trial, titled "A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome," has been completed. The trial enrolled 3,037 participants across multiple countries.
Acetylsalicylic acid is the chemical name for aspirin, a widely used medication. In the context of this clinical development program, Johnson & Johnson is studying acetylsalicylic acid as a treatment for Acute Coronary Syndrome. The drug is being evaluated in a Phase 2 clinical trial to assess its safety and efficacy in this patient population.